Syngene International Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹1,036Cr
- +1.8% YoY
- +13% QoQ
- Net profit
- ₹148Cr
- −19.1% YoY
- +886.7% QoQ
- Margin
- 29%
- −5 pp YoY
- +6 pp QoQ
Top 10 Healthcare Services companies on management guidance
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
1 of 3 strong
The short version
FY27 guidance expects broadly flat revenue performance compared to FY26, with growth weighted towards the second half of the year as new contracts ramp up. FY27 is expected to have broadly flat revenue growth with EBITDA margins maintained in the mid-20s % through disciplined cost management.
From Syngene International Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY27 guidance expects broadly flat revenue performance compared to FY26, with growth weighted towards the second half of the year as new contracts ramp up.
- The adverse impact of Librela destocking is expected to continue through H1 FY27, with near-zero Librela volumes anticipated in the first two quarters and only minor volumes thereafter.
- Post FY27, Syngene expects to reset its baseline and enter a phase of sustainable and higher growth, driven by pipeline maturation and investments in new modalities like peptides, ADCs, and biologics.
- The company anticipates stronger growth from FY28 onwards as the Librela effect washes out and new capabilities begin to deliver.
2 more points from Syngene International Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Syngene International Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Syngene continues to invest in building capabilities and technologies to become an integrated solution provider.
- In Q4 FY26, invested $10 million focused 50% on research services (capability build, contractual obligations, dedicated centers, and maintenance).
- About 40% of capex was directed to the CDMO business.
- The remaining capex was toward digitization, automation, and common infrastructure.
- Commissioned a new commercial scale facility for liquid-filled hard gelatin capsules, enhancing oral solid dosage capabilities.
- Expanded Bengaluru biologics facility with a GMP bioconjugation suite for end-to-end antibody drug conjugates manufacturing.
- Bayview biologics facility in the U.S. is progressing toward operationalization in FY27 with ongoing investments and trial runs.
2 more points from Syngene International Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Syngene International Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- It mentions a "healthy pipeline of deal flows" expected to translate into stronger growth from FY28 onwards.
- Syngene is seeing encouraging interest and increased client interactions at their biologics facilities (Bayview and Unit 3), indicating a growing order pipeline.
- The extended long-term collaboration with Bristol-Myers Squibb through 2035 suggests a stable and strategic order flow over the next decade.
- The company is actively engaging with prospective customers as the Bayview biologics facility in the U.S. moves toward operationalization, which supports future order growth.
Syngene International Ltd — Quarterly revenue & net profit
Syngene International Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,036 | 1,018 | +1.8% | 917 | +13% |
| Operating profit (EBITDA) | 303 | 344 | -11.9% | 209 | +45% |
| Operating margin | 29% | 34% | -5 pp | 23% | +6 pp |
| Profit before tax | 196 | 240 | -18.3% | 28 | +600% |
| Net profit (PAT) | 148 | 183 | -19.1% | 15 | +886.7% |
| EPS (₹) | 3.67 | 4.55 | -19.3% | 0.37 | +891.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹833 Cr, net profit ₹32 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Syngene International's management said in earlier quarters
Others in Healthcare Services this season
- Suven Life Sciences (Q4 FY26)
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su
- Invicta Diagnostic (Q4 FY26)
Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnostic's Q4 FY26 earnings…
- KMC Speciality (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
- Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Syngene International Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Syngene International Ltd Q4 FY26 results?
FY27 guidance expects broadly flat revenue performance compared to FY26, with growth weighted towards the second half of the year as new contracts ramp up. FY27 is expected to have broadly flat revenue growth with EBITDA margins maintained in the mid-20s % through disciplined cost management.
What is Syngene International Ltd share price analysis?
Syngene International Ltd currently shows a neutral. The stock trades at a P/E of 55.5 with a market cap of ₹16,427 Cr. Investors should review the full earnings analysis for detailed insights.
Is Syngene International Ltd planning capital expenditure?
Syngene continues to invest in building capabilities and technologies to become an integrated solution provider. - In Q4 FY26, invested $10 million focused 50% on research services (capability build, contractual obligations, dedicated centers, and maintenance). - About 40% of capex was directed to the CDMO business. - The remaining capex was toward digitization, automation, and common infrastructure. - Commissioned a new commercial scale facility for liquid-filled hard gelatin capsules, enhancing oral solid dosage capabilities. - Expanded Bengaluru biologics facility with a GMP bioconjugation suite for end-to-end antibody drug conjugates manufacturing. - Bayview biologics facility in the U.S.
Keep Syngene International Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
